Adverum Biotechnologies Inc (ADVM)
6.94
+0.33
(+4.99%)
USD |
NASDAQ |
Sep 27, 16:00
6.96
+0.02
(+0.29%)
After-Hours: 20:00
Adverum Biotechnologies SG&A Expense (Annual): 49.92M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 49.92M |
| December 31, 2022 | 57.86M |
| December 31, 2021 | 64.44M |
| December 31, 2020 | 44.64M |
| December 31, 2019 | 28.38M |
| December 31, 2018 | 24.56M |
| Date | Value |
|---|---|
| December 31, 2017 | 20.86M |
| December 31, 2016 | 24.36M |
| December 31, 2015 | 22.11M |
| December 31, 2014 | 7.998M |
| December 31, 2013 | 1.783M |
| December 31, 2012 | 0.536M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
28.38M
Minimum
2019
64.44M
Maximum
2021
49.05M
Average
49.92M
Median
2023
SG&A Expense (Annual) Benchmarks
| EyePoint Pharmaceuticals Inc | 51.79M |
| Cassava Sciences Inc | 16.53M |
| Regenxbio Inc | 88.49M |
| Editas Medicine Inc | 69.65M |
| Apellis Pharmaceuticals Inc | 500.82M |